Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zoom Video

Investors need to get used to this tug of war in the months ahead.

Moderna, Zoom Reveal the Nasdaq's Split Personality

With COVID-19's worldwide case count officially exceeding 11 million and waves of closures sweeping U.S. states in an attempt to stifle the resurgent threat, an island of good news has appeared in what looks increasingly like a sea of bad tidings. Following Pfizer's announcement last week of a COVID-19 vaccine showing 90 percent effectiveness in […]

Moderna Solved The Supply Chain Problem, But Will Consumers Embrace A Covid-19 Vaccine?

Moderna's (MRNA) COVID-19 vaccine candidate mRNA-1273 proves its vaccine efficacy of 94.5% in the late-stage COVE study. The stock appreciates in pre-market trading following this news.

Moderna's (MRNA) Coronavirus Vaccine Shows 94.5% Efficacy Rate

The European Commission wants to reach a deal with Moderna for the supply of millions of doses of its COVID-19 vaccine candidate for a price below $25 per dose, an EU official involved in the talks said.

Exclusive: EU seeks Moderna COVID vaccine deal at below $25 per dose, source says

Moderna Inc's COVID-19 vaccine will be easy to distribute, particularly to rural areas, because it can be stored for one month at standard refrigerator temperatures, Matthew Hepburn, head of vaccines for the U.S. Operation Warp Speed program, said on Monday.

Moderna vaccine stability enables distribution in rural America: U.S. official

Pfizer

Early data has indicated Pfizer's vaccine could be up to 90% effective and Moderna's could be more than 94% effective.

Former FDA Commissioner Says Pandemic Could ‘Effectively End In 2021' If Pfizer, Moderna Vaccines Live Up To Early Data

More excellent news from the world of science generally, and defeating the coronavirus pandemic in specific: Moderna (MRNA Quick QuoteMRNA - Free Report) , the messenger RNA (mRNA) biotech company based in Cambridge, MA, has announced a 94.5% effective rate for its Covid-19 vaccine. The company now intends on filing for emergency authorization in the United States. Shares are up for MRNA 14% in the early market on the news.

Positive Developments on COVID-19 Treatment Front

  Biotech giant Moderna on Monday announced that its COVID-19 vaccine was 94.

Moderna's COVID-19 vaccine, which got its start in Seattle, is 94.5% effective in trials

Last Thursday, Moderna Inc (NASDAQ:MRNA) gave investors an update regarding their COVID-19 vaccine candidate , but were unable to report on the vaccine's effectiveness.

MRNA Soars to Record Highs After COVID-19 Vaccine Update

The company now intends on filing for emergency authorization in the United States. Shares are up for MRNA 14% in the early market on the news.

Moderna (MRNA) Covid Drug Proves 94.5% Efficacy

Moderna Inc. (NASDAQ: MRNA) said on Monday that preliminary data from its phase three trial suggests its candidate COVID-19 vaccine is effective in over 94% of the cases. CEO Stephane Bancel called the preliminary results a “game-changer” in the global battle against the Coronavirus pandemic.

Moderna says its COVID-19 vaccine is effective in over 94% of the cases

If Moderna can make a billion doses in 2021, its vaccine could add nearly $35 billion to its top line

Moderna Covid-19 Vaccine Could Add Nearly $35 Billion To Its Revenues

Noubar Afeyan, Moderna co-founder and chairman, says the company's innovations enable it to "keep the vaccine under refrigeration conditions for up to 30 days," enabling broad distribution.

Moderna chairman: We don't need deep-freeze conditions for vaccine

Pfizer shares fell nearly 3 percent in the pre-market trading Monday following Moderna's announcement.

Moderna Inc. (MRNA) says its Covid-19 vaccine more than 94 percent effective in Phase-III trials

MRNA stock is off to a great start Monday thanks to news its coronavirus vaccine candidate is almost 95% effective. The post MRNA Stock: Moderna Shares Surge on Covid-19 Vaccine News appeared first on InvestorPlace.

MRNA Stock: Moderna Shares Surge on Covid-19 Vaccine News

Biotech firm Moderna Inc. (NASDAQ: MRNA) Monday reported initial results from a Phase 3 trial of its COVID-19 vaccine (mRNA-1273) that proved 94.5% effective in preventing the infection.

Moderna's COVID-19 Vaccine Results Lift Blue Chips

Shares of Moderna (NASDAQ: MRNA) exploded 15% in pre-open Monday after the company said its Covid-19 vaccine showed 94.5% efficacy in testing.  Fundamental analysis: “As good as it gets” Moderna said its coronavirus vaccine was 94.5% effective making it the second highly-efficient vaccine after the one developed by Pfizer and BioNTech.

Moderna stock price soars to record highs as Covid-19 vaccine shows 94.5% efficacy

The public health leader stressed the need to continue other methods of disease control, like contact tracing, isolating infected patients and testing.

WHO Chief Warns Vaccine Won't End Covid-19 Pandemic As Moderna, Pfizer Announce Early Successes

HHS Secretary Alex Azar said Monday that the FDA will move "as quickly as possible" to issue an authorization for Covid-19 vaccines from Pfizer and Moderna.

HHS Secretary Azar says the FDA will move 'as quickly as possible' to clear Moderna and Pfizer's Covid vaccines

The European Union Health Commissioner Stella Kyriakides said the EU was in talks with Moderna to secure doses of its COVID-19 vaccine candidate but negotiations had not been wrapped up yet.

EU says talks with Moderna on COVID-19 vaccine candidate are ongoing

The Moderna trial includes 30,000 participants in the US.

Moderna coronavirus vaccine is 94.5% effective, company says

Its 94.5% efficacy estimate appears competitive with results that Pfizer and BioNTech reported last week.

Moderna Reports Successful Coronavirus Vaccine Results

Moderna CEO Stephane Bancel said his company's coronavirus vaccine has demonstrated a "gamechanger" safety record in ongoing studies, along with 94.5% effectiveness.

Moderna CEO cheers coronavirus vaccine safety as 'gamechanger,' with 20M doses available by end of year

Moderna Inc. said Monday its COVID-19 vaccine candidate met its primary endpoint in a Phase 3 trial, demonstrating 94.5% efficacy, a far higher benchmark than originally expected, sparking a broad-based market rally.

Moderna's COVID-19 vaccine candidate achieves 94.5% efficacy in late-stage trial, sparking market rally

One week after Pfizer and BioNTech announced the efficacy of their COVID-19 vaccine, biotech Moderna has done the same, as the world grapples with the pandemic.

News for Moderna Stock (MRNA)